Eiger BioPharmaceuticals Inc

NASDAQ EIGRQ

Data sourced from iex and EODHD
Download Data

Eiger BioPharmaceuticals Inc Non-current Assets to Total Assets Ratio 2 year CAGR for the quarter ending December 31, 2023

Eiger BioPharmaceuticals Inc Non-current Assets to Total Assets Ratio 2 year CAGR is NA for the quarter ending December 31, 2023. The non-current assets to total assets ratio measures the proportion of a company's non-current assets to its total assets. It is calculated by dividing the total non-current assets by the total assets. This ratio provides insights into the composition of a company's asset base and the extent to which it relies on non-current assets, such as property, plant, and equipment, to generate revenue. A higher ratio suggests a greater proportion of non-current assets, indicating potential long-term stability and investment in fixed assets. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: EIGRQ

Eiger BioPharmaceuticals Inc

CEO -
IPO Date Jan. 30, 2014
Location United States
Headquarters 2155 Park Boulevard, Palo Alto, CA, United States, 94306
Employees 25
Sector Healthcare
Industry Biotechnology
Description

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia. The company is headquartered in Palo Alto, California. On April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.

StockViz Staff

September 19, 2024

Any question? Send us an email